NASDAQ
06.11.26 | 21:59
1,850 US-Dollar
-1,07 % -0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.10. | Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure | 1 | Investing.com | ||
| 02.10. | Foghorn Therapeutics-Aktie stürzt nach gescheiterter Lilly-Kooperation und Analysten-Downgrades ab | 13 | Investing.com Deutsch | ||
| 02.10. | Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt | 2 | Investing.com | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.10. | Wedbush cuts Foghorn Therapeutics stock rating on drug setback | 2 | Investing.com | ||
| 02.10. | Guggenheim cuts Foghorn Therapeutics price target on drug setback | 1 | Investing.com | ||
| 01.10. | Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt | 4 | Investing.com | ||
| 01.10. | TD Cowen stuft Foghorn Therapeutics nach Studienabbruch auf "Halten" herab | 4 | Investing.com Deutsch | ||
| 01.10. | Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation | 3 | Investing.com | ||
| 01.10. | Citizens stuft Foghorn Therapeutics nach Einstellung von Medikamentenentwicklung herab | 3 | Investing.com Deutsch | ||
| 01.10. | Stifel senkt Kursziel für Foghorn Therapeutics nach Pipeline-Neuausrichtung | 1 | Investing.com Deutsch | ||
| 01.10. | Stifel cuts Foghorn Therapeutics stock price target on pipeline shift | 1 | Investing.com | ||
| 01.10. | Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal | 2 | Benzinga.com | ||
| 01.10. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities | 576 | GlobeNewswire (Europe) | Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective... ► Artikel lesen | |
| 01.10. | Foghorn Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.09. | Citizens bestätigt Einstufung für Foghorn Therapeutics vor wichtigen Studiendaten | 17 | Investing.com Deutsch | ||
| 17.09. | Citizens reiterates Foghorn Therapeutics stock rating on trial data | 2 | Investing.com | ||
| 17.08. | Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 | 2 | Investing.com | ||
| 06.08. | Foghorn Therapeutics GAAP EPS of -$0.10 beats by $0.14, revenue of $16.1M beats by $8.17M | 2 | Seeking Alpha | ||
| 06.08. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 9,710 | +0,31 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,050 | -3,76 % | Aktien New York Ausblick: Erholungsversuch vor US-Zwischenwahlen | NEW YORK (dpa-AFX) - Nach den herben Verlusten vom Freitag und vor den am Dienstag anstehenden Zwischenwahlen in den USA dürften die US-Börsen am Montag einen Erholungsversuch starten. Im Anlegerfokus... ► Artikel lesen | |
| INFLARX | 1,175 | +1,29 % | InflaRx: Phase-1-Daten veröffentlicht - die Aktie bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 10,180 | 0,00 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDITAS MEDICINE | 2,270 | -1,73 % | Jones Trading initiates Editas Medicine stock coverage with buy rating | ||
| NUREXONE BIOLOGIC | 0,300 | -7,69 % | 2 Seiten der Läsion, p 0,01 und p 0,04: Warum NurExone neben Bewegung auch Myelin misst | ||
| GERON | 0,892 | +0,61 % | GERON CORP - 10-Q, Quarterly Report | ||
| IBIO | 0,649 | -2,41 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 7,620 | -1,68 % | ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ | First patients treated in Germany and Austria, with commercial support from Accord Healthcare
Treatment milestone follows European Commission's February 2026 conditional marketing authorization... ► Artikel lesen | |
| IMMATICS | 5,670 | -0,70 % | Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting | IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and... ► Artikel lesen | |
| MYRIAD GENETICS | 5,300 | 0,00 % | MYRIAD GENETICS INC - 10-Q, Quarterly Report | ||
| MANNKIND | 3,462 | -0,89 % | Cantor Fitzgerald hebt Kursziel für MannKind wegen Tyvaso-Dynamik auf 10 US-Dollar an | ||
| GINKGO BIOWORKS | 10,065 | -0,54 % | Ginkgo Bioworks Holdings GAAP EPS of -$0.64 beats by $0.22, revenue of $27.7M beats by $6.19M | ||
| IMMUNIC | 6,426 | -8,41 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in November | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in November
02.11.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,200 | -0,14 % | IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,850 Euro und damit -1,07 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.